We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+9.7%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$97.2M
AUM Growth
+$5.62M
Cap. Flow
+$348K
Cap. Flow %
0.36%
Top 10 Hldgs %
67.75%
Holding
59
New
8
Increased
8
Reduced
8
Closed
10

Top Buys

Rank Stock Value
1
WINT
Windtree Therapeutics Inc
WINT
+$8.21M
2
NXTM
NxStage Medical Inc.
NXTM
+$1.5M
3
MTEM
Molecular Templates, Inc.
MTEM
+$1.28M
4
ACHV icon
Achieve Life Sciences
ACHV
+$895K
5
PCYC
PHARMACYCLICS INC
PCYC
+$789K

Top Sells

Rank Stock Value
1
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$2.74M
2
CRIS icon
Curis
CRIS
+$1.3M
3
KBIO
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
+$1.13M
4
BEAT
BioTelemetry, Inc.
BEAT
+$867K
5
RXII
GALENA BIOPHARMA INC COM
RXII
+$855K

Sector Composition

Rank Sector Weight
1 Healthcare 57.39%
2 Financials 1.3%
3 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DMK
26
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$799K 0.82%
+1,786
New +$783K
UPI
27
DELISTED
UROPLASTY INC-NEW
UPI
$790K 0.81%
289,332
– –
CLVS
28
DELISTED
Clovis Oncology, Inc.
CLVS
$759K 0.78%
+12,600
New +$685K
EXAC
29
DELISTED
Exactech Inc
EXAC
$752K 0.77%
31,636
-2,000
-6% -$45.6K
NSPR icon
30
InspireMD
NSPR
$31.4M
– –
0
– –
ICPT
31
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$655K 0.67%
9,598
– –
DSCI
32
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$617K 0.64%
57,009
– –
SRGA
33
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$591K 0.61%
5,569
– –
KERX
34
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$570K 0.59%
44,000
-30,100
-41% -$359K
DYAX
35
DELISTED
DYAX CORPORATION
DYAX
$569K 0.59%
75,500
– –
DVAX
36
DELISTED
Dynavax Technologies
DVAX
$568K 0.58%
+29,000
New +$424K
MASI
37
DELISTED
Masimo
MASI
$512K 0.53%
17,500
– –
CRIS icon
38
Curis
CRIS
$9.71M
$423K 0.44%
75
-190
-72% -$1.3M
BAXS
39
DELISTED
BAXANO SURGICAL INC COM STK (DE)
BAXS
$340K 0.35%
336,351
– –
TGTX icon
40
TG Therapeutics
TGTX
$8.19B
$293K 0.3%
75,000
– –
TOVX icon
41
Theriva Biologics
TOVX
$10.1M
$283K 0.29%
+21
New +$265K
PTN
42
Palatin Technologies
PTN
$14.4M
$253K 0.26%
276
-24
-8% -$20K
CEMI
43
DELISTED
Chembio diagnostics, Inc.
CEMI
$186K 0.19%
+55,202
New +$195K
RVP icon
44
Retractable Technologies
RVP
$20.1M
$62K 0.06%
+20,000
New +$55.8K
NVAX icon
45
Novavax
NVAX
$1.21B
– –
-10,500
Closed -$662K
PALI icon
46
Palisade Bio
PALI
$341M
– –
0
– -$847K
TNXP icon
47
Tonix Pharmaceuticals
TNXP
$152M
– –
0
– -$164K
BIOL
48
DELISTED
Biolase, Inc.
BIOL
– –
-9
Closed -$213K
ACGN
49
DELISTED
Aceragen Inc
ACGN
– –
-1,472
Closed -$348K
ACHN
50
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-121,800
Closed -$368K
1
2
3

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DWML
Decker Wealth Management LLC Nashville, Tennessee $441M AUM

DAFNA Capital Management's Q4 2013 Portfolio in Review

As of Q4 2013, DAFNA Capital Management held 59 positions worth $97.2M, up 6.1% from $91.5M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

DAFNA Capital Management's Q4 2013 filing shows 8 new, 8 increased, 8 reduced and 10 closed positions. Its largest new stake was Molecular Templates, Inc.: 1,700 shares worth $1.31M. The largest sale was Ariad Pharmaceuticals Inc, an estimated $2.74M.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 60% a quarter earlier, followed by Financials and Communication Services.

  • DAFNA Capital Management's largest Q4 2013 buy was Molecular Templates, Inc.: 1,700 shares worth $1.31M.
  • DAFNA Capital Management added most to Windtree Therapeutics Inc in Q4 2013, an estimated $8.21M increase.
  • DAFNA Capital Management's biggest Q4 2013 reduction was Curis, cutting an estimated $1.3M.
  • DAFNA Capital Management fully exited Ariad Pharmaceuticals Inc in Q4 2013, selling an estimated $2.74M.
  • DAFNA Capital Management's ten largest holdings make up 68% of its $97.2M portfolio in Q4 2013.
  • DAFNA Capital Management opened 8 new positions and closed 10 in Q4 2013.
  • DAFNA Capital Management's portfolio value rose 6.1% quarter-over-quarter to $97.2M.

Based on DAFNA Capital Management's 13F filing for Q4 2013, filed 14 Feb 2014.